Korbinian Maria Riedhammer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Korbinian Maria Riedhammer has a total of 841 co-authors. Here are the top co-authors by number of shared publications:
- Julia Hoefele
Institute of Human Genetics LMU University Hospital, LMU Munich Munich Germany
15 shared publications - Dominik Sebastian Westphal
Department of Human Genetics Landeskrankenhaus University Hospital, Paracelsus Medical University Salzburg Austria
6 shared publications Jasmina Ćomić
Institute of Human Genetics, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Munich, Germany
6 shared publications- Matias Wagner
Institute of Human Genetics, School of Medicine and Health Technical University of Munich Munich Germany
6 shared publications Thomas Meitinger
Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany
6 shared publicationsUwe Heemann
6 shared publications
Latest Publications
- Open Access
Mapping intronic mutational hotspots by in silico mutagenesis enables single antisense oligonucleotide correction of multiple variants
Deep intronic variants remain an understudied class of pathogenic variation, primarily due to their absence from standard exome and gene panel datasets and the complexity of non-coding genome interpretation. We hypothesized that pathogenic deep intronic variants are not randomly distributed but instead cluster within intronic "hotspots" inherently prone to pseudoexon activation, and that mapping such regions could improve molecular diagnosis. Importantly, such intronic hotspots nominate targets for antisense oligonucleotide (ASO) therapy. Using X-linked Alport syndrome as a proof-of-concept model and based on our previous work, we screened unsolved patients across multiple European diagnostic centers for variants within a defined region of COL4A5 intron 6. We identified eight independent variants in more than 35 affected individuals from ten unrelated families, which led to two pseudoexon inclusion events, both using the same strong cryptic splice donor site. In all, RNA sequencing and/or minigene assays confirmed aberrant splicing, even when prediction tools were discordant or fell below clinical thresholds. A single ASO targeting the shared donor site restored normal COL4A5 mRNA and α5(IV) collagen protein expression in patient-derived cells regardless of the causative variant. Extending this analysis gene-wide using the AlphaGenome sequence-to-function model, we confirmed intron 6 as one of the most critical COL4A5 splicing hotspot and identified additional potential hotspots harboring novel predicted spliceogenic variants. This gene-agnostic framework establishes a systematic strategy for identifying intronic mutational hotspots and matching patients to scalable, mutation-agnostic ASO-based precision therapies.
Open AccessMapping intronic mutational hotspots by in silico mutagenesis enables single antisense oligonucleotide correction of multiple variants
Deep intronic variants remain an understudied class of pathogenic variation, primarily due to their absence from standard exome and gene panel datasets and the complexity of non-coding genome interpretation. We hypothesized that pathogenic deep intronic variants are not randomly distributed but instead cluster within intronic "hotspots" inherently prone to pseudoexon activation, and that mapping such regions could improve molecular diagnosis. Importantly, such intronic hotspots nominate targets for antisense oligonucleotide (ASO) therapy. Using X-linked Alport syndrome as a proof-of-concept model and based on our previous work, we screened unsolved patients across multiple European diagnostic centers for variants within a defined region of COL4A5 intron 6. We identified eight independent variants in more than 35 affected individuals from ten unrelated families, which led to two pseudoexon inclusion events, both using the same strong cryptic splice donor site. In all, RNA sequencing and/or minigene assays confirmed aberrant splicing, even when prediction tools were discordant or fell below clinical thresholds. A single ASO targeting the shared donor site restored normal COL4A5 mRNA and α5(IV) collagen protein expression in patient-derived cells regardless of the causative variant. Extending this analysis gene-wide using the AlphaGenome sequence-to-function model, we confirmed intron 6 as one of the most critical COL4A5 splicing hotspot and identified additional potential hotspots harboring novel predicted spliceogenic variants. This gene-agnostic framework establishes a systematic strategy for identifying intronic mutational hotspots and matching patients to scalable, mutation-agnostic ASO-based precision therapies.
- 24 July 2026
- Published by Springer Nature in Die Nephrologie
- Vol. 21 (5) , 302-311
Lang bekannt, in neuem Licht: Alport-Syndrom und Alport-Spektrum-Erkrankung
- 24 July 2026
- Published by Springer Nature in Die Nephrologie
- Vol. 21 (5) , 302-311
Lang bekannt, in neuem Licht: Alport-Syndrom und Alport-Spektrum-Erkrankung
- Open Access
- 18 March 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (5) , 630-638
Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results
“Alport spectrum disorder” describes a phenotypically and genotypically multifaceted disease entity encompassing classic autosomal recessive and X-linked Alport syndrome (AS) but also more heterogenous and typically milder, yet not benign, hematuric phenotypes like autosomal dominant AS, formerly also known as thin basement membrane nephropathy (TBMN). Alport spectrum disorder is associated with disease-causing variants in the type IV collagen genes COL4A3 , COL4A4 and COL4A5 . Variants and genotypes, reported by a genetic diagnostics lab between 2009 and 2014, of 91 index cases with the clinical tentative diagnosis of AS (66/91), TBMN (21/91), or AS/TBMN (not specified further; 4/91), were reassessed based on 2015 ACMG (American College of Medical Genetics and Genomics) criteria and current amendments. 80 different variants, all originally reported as “mutations”, and their genotypes have been reassessed ( COL4A3 : 21/80, COL4A4 : 15/80, COL4A5 : 44/80). In 10/80 variants, classification changed from disease-causing to variant of uncertain significance (VUS). 69/91 (76%) index cases included in the analysis could be classified as solved. 22/91 (24%) index cases had an ambiguous result either on variant, genotype, or both variant and genotype level. VUS cases had a significantly more limited phenotype (e.g., isolated microscopic hematuria) compared to non-downgraded cases (e.g., additional extrarenal manifestations). Reassessment of variants/genotypes in this study showed a significant reduction in unequivocal genetic diagnoses highlighting variant and genotype interpretation as a dynamic process. Genetic reports of individuals with suspected Alport spectrum disorder, especially those obtained in the pre-ACMG criteria era, should therefore be critically evaluated.
- 18 March 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (5) , 630-638
Open AccessSystematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results
“Alport spectrum disorder” describes a phenotypically and genotypically multifaceted disease entity encompassing classic autosomal recessive and X-linked Alport syndrome (AS) but also more heterogenous and typically milder, yet not benign, hematuric phenotypes like autosomal dominant AS, formerly also known as thin basement membrane nephropathy (TBMN). Alport spectrum disorder is associated with disease-causing variants in the type IV collagen genes COL4A3 , COL4A4 and COL4A5 . Variants and genotypes, reported by a genetic diagnostics lab between 2009 and 2014, of 91 index cases with the clinical tentative diagnosis of AS (66/91), TBMN (21/91), or AS/TBMN (not specified further; 4/91), were reassessed based on 2015 ACMG (American College of Medical Genetics and Genomics) criteria and current amendments. 80 different variants, all originally reported as “mutations”, and their genotypes have been reassessed ( COL4A3 : 21/80, COL4A4 : 15/80, COL4A5 : 44/80). In 10/80 variants, classification changed from disease-causing to variant of uncertain significance (VUS). 69/91 (76%) index cases included in the analysis could be classified as solved. 22/91 (24%) index cases had an ambiguous result either on variant, genotype, or both variant and genotype level. VUS cases had a significantly more limited phenotype (e.g., isolated microscopic hematuria) compared to non-downgraded cases (e.g., additional extrarenal manifestations). Reassessment of variants/genotypes in this study showed a significant reduction in unequivocal genetic diagnoses highlighting variant and genotype interpretation as a dynamic process. Genetic reports of individuals with suspected Alport spectrum disorder, especially those obtained in the pre-ACMG criteria era, should therefore be critically evaluated.
- Open Access
Clinical, in vitro, and in vivo evidence of WAPL as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorder
Cohesin is a fundamental genome-organizing complex that orchestrates three-dimensional chromosome folding and gene expression via DNA loop extrusion. Alterations to genes encoding cohesin subunits and cohesin loaders cause Mendelian disorders, including Cornelia de Lange syndrome (CdLS). By contrast, disruption of factors that remove cohesin from DNA, including WAPL and its binding partners PDS5A and PDS5B , have not yet been associated with human disease. Here, we explored the relevance of these cohesin release factors in Mendelian disease by establishing a rare disease cohort of deeply phenotyped individuals with heterozygous, predicted damaging variants in WAPL (n=27), PDS5A (n=8), and PDS5B (n=8), by modeling WAPL deficiency in human cell lines and mice, and by aggregating rare disease association statistics from consortia studies. We identified a WAPL -related disorder characterized by developmental delay, intellectual disability, and risk of other developmental anomalies including clubfoot. Similarities between individuals with damaging WAPL variants and those with large, recurrent 10q22.3q23.2 (10q) deletions (which encompass WAPL ) nominate WAPL as a driver gene within this genomic disorder region. While carriers of PDS5A or PDS5B variants exhibited features of developmental disorders, neither cohort-based statistics nor case phenotyping associated these genes with specific phenotypes. We used CRISPR engineering to generate truncating variants in WAPL , as well the 7.8 Mb 10q deletion or duplication in human iPSCs and induced neurons. Transcriptomic analyses identified differentially expressed genes in both models, with highly significant overlap between WAPL haploinsufficiency and 10q deletion signatures. Mice with 50% residual Wapl expression exhibited mild deficits of growth and learning/memory, whereas those with 25% residual Wapl expression displayed birth defects and postnatal lethality, revealing a dosage liability threshold below the level of heterozygosity. In summary, we delineated a novel genetic condition caused by cohesin release factor deficiency, nominated WAPL as a driver gene within a genomic disorder region, and further illuminated dosage sensitivity of human cohesin.
Open AccessClinical, in vitro, and in vivo evidence of WAPL as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorder
Cohesin is a fundamental genome-organizing complex that orchestrates three-dimensional chromosome folding and gene expression via DNA loop extrusion. Alterations to genes encoding cohesin subunits and cohesin loaders cause Mendelian disorders, including Cornelia de Lange syndrome (CdLS). By contrast, disruption of factors that remove cohesin from DNA, including WAPL and its binding partners PDS5A and PDS5B , have not yet been associated with human disease. Here, we explored the relevance of these cohesin release factors in Mendelian disease by establishing a rare disease cohort of deeply phenotyped individuals with heterozygous, predicted damaging variants in WAPL (n=27), PDS5A (n=8), and PDS5B (n=8), by modeling WAPL deficiency in human cell lines and mice, and by aggregating rare disease association statistics from consortia studies. We identified a WAPL -related disorder characterized by developmental delay, intellectual disability, and risk of other developmental anomalies including clubfoot. Similarities between individuals with damaging WAPL variants and those with large, recurrent 10q22.3q23.2 (10q) deletions (which encompass WAPL ) nominate WAPL as a driver gene within this genomic disorder region. While carriers of PDS5A or PDS5B variants exhibited features of developmental disorders, neither cohort-based statistics nor case phenotyping associated these genes with specific phenotypes. We used CRISPR engineering to generate truncating variants in WAPL , as well the 7.8 Mb 10q deletion or duplication in human iPSCs and induced neurons. Transcriptomic analyses identified differentially expressed genes in both models, with highly significant overlap between WAPL haploinsufficiency and 10q deletion signatures. Mice with 50% residual Wapl expression exhibited mild deficits of growth and learning/memory, whereas those with 25% residual Wapl expression displayed birth defects and postnatal lethality, revealing a dosage liability threshold below the level of heterozygosity. In summary, we delineated a novel genetic condition caused by cohesin release factor deficiency, nominated WAPL as a driver gene within a genomic disorder region, and further illuminated dosage sensitivity of human cohesin.
- Open Access
A kidney specific mouse model to study the effects of in vivo induction of Yamanaka factors
Introduction: Maladaptive repair after acute kidney injury (AKI) leads to fibrosis and chronic kidney disease (CKD). Improving the resilience and stimulating tissue repair after injury is crucial to prevent AKI-to-CKD transition. Using a combination of transcription factors (Yamanaka factors Oct4, Klf4 and Sox2, “OKS” ) to partially reprogram tissues and enhance regeneration in vivo , could be a promising approach as shown by amelioration after various organ injury, yet not investigated for AKI to date. Methods: We used a ubiquitously and kidney-specific transgenic mouse model to investigate OKS expression in kidney. In a kidney-specific model using Pax8-Cre, we then induced AKI via aristolochic acid (AA), simultaneously expressing OKS to determine potential protective effects after kidney injury. Results: We show that a ubiquitously expressing OKS -mouse model was not suitable due to toxic effects and limited kidney expression. In the Pax8 -Cre mouse model, we observed expression almost exclusively to proximal tubules. While induction for more than 3 days caused dysplastic tumor formation, an induction regimen limited to 3 days was not able to improve phenotypic outcome after AA-injury. Conclusion: Partial reprogramming of the kidney using OKS is feasible; however, it requires a delicate balance to the risk of oncogenic transformation. Determine a dose that effectively promotes repair without crossing the threshold into harmful effects remains a major challenge, posing significant safety concerns for translating the approach to humans in the near future.
Open AccessA kidney specific mouse model to study the effects of in vivo induction of Yamanaka factors
Introduction: Maladaptive repair after acute kidney injury (AKI) leads to fibrosis and chronic kidney disease (CKD). Improving the resilience and stimulating tissue repair after injury is crucial to prevent AKI-to-CKD transition. Using a combination of transcription factors (Yamanaka factors Oct4, Klf4 and Sox2, “OKS” ) to partially reprogram tissues and enhance regeneration in vivo , could be a promising approach as shown by amelioration after various organ injury, yet not investigated for AKI to date. Methods: We used a ubiquitously and kidney-specific transgenic mouse model to investigate OKS expression in kidney. In a kidney-specific model using Pax8-Cre, we then induced AKI via aristolochic acid (AA), simultaneously expressing OKS to determine potential protective effects after kidney injury. Results: We show that a ubiquitously expressing OKS -mouse model was not suitable due to toxic effects and limited kidney expression. In the Pax8 -Cre mouse model, we observed expression almost exclusively to proximal tubules. While induction for more than 3 days caused dysplastic tumor formation, an induction regimen limited to 3 days was not able to improve phenotypic outcome after AA-injury. Conclusion: Partial reprogramming of the kidney using OKS is feasible; however, it requires a delicate balance to the risk of oncogenic transformation. Determine a dose that effectively promotes repair without crossing the threshold into harmful effects remains a major challenge, posing significant safety concerns for translating the approach to humans in the near future.
- Open Access
- 24 June 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (7) , 1790-1791
Author Correction: Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings
- 24 June 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (7) , 1790-1791
Open AccessAuthor Correction: Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings
- Open Access
- 21 April 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (7) , 2384-2393
Estimating Lifetime Risk of Autosomal Recessive Kidney Diseases Using Population-Based Genotypic Data
- 21 April 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (7) , 2384-2393
Open AccessEstimating Lifetime Risk of Autosomal Recessive Kidney Diseases Using Population-Based Genotypic Data
- Open Access
- 12 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (5) , 588-594
Further delineation of the SCAF4-associated neurodevelopmental disorder
While mostly de novo truncating variants in SCAF4 were recently identified in 18 individuals with variable neurodevelopmental phenotypes, knowledge on the molecular and clinical spectrum is still limited. We assembled data on 50 novel individuals with SCAF4 variants ascertained via GeneMatcher and personal communication. With detailed evaluation of clinical data, in silico predictions and structural modeling, we further characterized the molecular and clinical spectrum of the autosomal dominant SCAF4-associated neurodevelopmental disorder. The molecular spectrum comprises 25 truncating, eight splice-site and five missense variants. While all other truncating variants were classified as pathogenic/likely pathogenic, significance of one C-terminal truncating variant, one splice-site variant and the missense variants remained unclear. Three missense variants in the CTD-interacting domain of SCAF4 were predicted to destabilize the domain. Twenty-three variants occurred de novo, and variants were inherited in 13 cases. Frequent clinical findings were mild developmental delay with speech impairment, seizures, and skeletal abnormalities such as clubfoot, scoliosis or hip dysplasia. Cognitive abilities ranged from normal IQ to severe intellectual disability (ID), with borderline to mild ID in the majority of individuals. Our study confirms the role of SCAF4 variants in neurodevelopmental disorders and further delineates the associated clinical phenotype.
- 12 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (5) , 588-594
Open AccessFurther delineation of the SCAF4-associated neurodevelopmental disorder
While mostly de novo truncating variants in SCAF4 were recently identified in 18 individuals with variable neurodevelopmental phenotypes, knowledge on the molecular and clinical spectrum is still limited. We assembled data on 50 novel individuals with SCAF4 variants ascertained via GeneMatcher and personal communication. With detailed evaluation of clinical data, in silico predictions and structural modeling, we further characterized the molecular and clinical spectrum of the autosomal dominant SCAF4-associated neurodevelopmental disorder. The molecular spectrum comprises 25 truncating, eight splice-site and five missense variants. While all other truncating variants were classified as pathogenic/likely pathogenic, significance of one C-terminal truncating variant, one splice-site variant and the missense variants remained unclear. Three missense variants in the CTD-interacting domain of SCAF4 were predicted to destabilize the domain. Twenty-three variants occurred de novo, and variants were inherited in 13 cases. Frequent clinical findings were mild developmental delay with speech impairment, seizures, and skeletal abnormalities such as clubfoot, scoliosis or hip dysplasia. Cognitive abilities ranged from normal IQ to severe intellectual disability (ID), with borderline to mild ID in the majority of individuals. Our study confirms the role of SCAF4 variants in neurodevelopmental disorders and further delineates the associated clinical phenotype.
- Open Access
- 9 December 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 877-891
Trio Exome Sequencing in VACTERL Association
- 9 December 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 877-891
Open AccessTrio Exome Sequencing in VACTERL Association
- Top Cited PapersOpen Access
- 22 July 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (8) , 1644-1653
Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings
Individuals with ultrarare disorders pose a structural challenge for healthcare systems since expert clinical knowledge is required to establish diagnoses. In TRANSLATE NAMSE, a 3-year prospective study, we evaluated a novel diagnostic concept based on multidisciplinary expertise in Germany. Here we present the systematic investigation of the phenotypic and molecular genetic data of 1,577 patients who had undergone exome sequencing and were partially analyzed with next-generation phenotyping approaches. Molecular genetic diagnoses were established in 32% of the patients totaling 370 distinct molecular genetic causes, most with prevalence below 1:50,000. During the diagnostic process, 34 novel and 23 candidate genotype–phenotype associations were identified, mainly in individuals with neurodevelopmental disorders. Sequencing data of the subcohort that consented to computer-assisted analysis of their facial images with GestaltMatcher could be prioritized more efficiently compared with approaches based solely on clinical features and molecular scores. Our study demonstrates the synergy of using next-generation sequencing and phenotyping for diagnosing ultrarare diseases in routine healthcare and discovering novel etiologies by multidisciplinary teams.
- 22 July 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (8) , 1644-1653
Top Cited PapersOpen AccessNext-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings
Individuals with ultrarare disorders pose a structural challenge for healthcare systems since expert clinical knowledge is required to establish diagnoses. In TRANSLATE NAMSE, a 3-year prospective study, we evaluated a novel diagnostic concept based on multidisciplinary expertise in Germany. Here we present the systematic investigation of the phenotypic and molecular genetic data of 1,577 patients who had undergone exome sequencing and were partially analyzed with next-generation phenotyping approaches. Molecular genetic diagnoses were established in 32% of the patients totaling 370 distinct molecular genetic causes, most with prevalence below 1:50,000. During the diagnostic process, 34 novel and 23 candidate genotype–phenotype associations were identified, mainly in individuals with neurodevelopmental disorders. Sequencing data of the subcohort that consented to computer-assisted analysis of their facial images with GestaltMatcher could be prioritized more efficiently compared with approaches based solely on clinical features and molecular scores. Our study demonstrates the synergy of using next-generation sequencing and phenotyping for diagnosing ultrarare diseases in routine healthcare and discovering novel etiologies by multidisciplinary teams.